I am a molecular bioengineer with experience in biochemistry, molecular biology, microbiology, phage engineering and genetics. Broadly, I am interested in the development of new  therapeutic platforms that can be easily adopted by other researchers. I am especially interested in developing therapeutics to treat infectious diseases that can be implemented outside of a hospital setting and in the developing world.
My undergraduate degree is in biochemistry and biophysics from Amherst College (Magna Cum Laude with distinction 2020) where I worked in the lab of Anthony Bishop researching the thermodynamic and kinetic impacts of non-conserved allosteric site cysteine residues in the human phosphatase SHP2 and related proteins. I then worked for two years (2020-2022) in the lab of Omar Abudayyeh and Jonathan Gootenberg at MIT, contributing to a variety of projects aimed at developing new tools for the programmable insertion of large DNA payloads into the genome of human cells, the endogenous tagging of proteins, and the modulation of gene expression levels through enhancer insertion and manipulation. The first paper from my research at MIT was published in Nature Biotechnology in November 2022, on which I am the lead author. After MIT, I spent a year (2022-2023) working as a research engineer at Eligo Bioscience in Paris, France, to gain experience in microbiology and microbiological bioengineering, as well as in the European biotechnology industry. 
I am currently a second year Chemical Biology Ph.D student at Harvard University in the Lab of Gaurav Gaiha, working on the development of soluble TCR based therapeutics for the treatment of cancer and infectious diseases.  

In my free time I enjoy playing cello in the Harvard Graduate Student Center Orchestra and trying to find anywhere in Cambridge open for dinner after 9pm.